UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000040988 |
|---|---|
| Receipt number | R000046802 |
| Scientific Title | Analysis on individual difference in pharmacokinetics of edoxaban and its metabolites, and investigation on predictive parameters of edoxaban response and adverse effects in Japanese patiens |
| Date of disclosure of the study information | 2020/08/31 |
| Last modified on | 2022/07/06 19:13:46 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Analysis on individual difference in pharmacokinetics of edoxaban and its metabolites, and investigation on predictive parameters of edoxaban response and adverse effects in Japanese patiens
Acronym
Analysis on individual difference in pharmacokinetics of edoxaban and its metabolites, and investigation on predictive parameters of edoxaban response and adverse effects in Japanese patiens
Scientific Title
Analysis on individual difference in pharmacokinetics of edoxaban and its metabolites, and investigation on predictive parameters of edoxaban response and adverse effects in Japanese patiens
Scientific Title:Acronym
Analysis on individual difference in pharmacokinetics of edoxaban and its metabolites, and investigation on predictive parameters of edoxaban response and adverse effects in Japanese patiens
Region
| Japan |
Condition
Condition
Atrial fibrillation
Classification by specialty
| Cardiology | Cardiovascular surgery |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
This study evaluate the interindividual variabilities of plasma dispositions of edoxaban and its metabolites determined by LC-MS/MS and clinical responses and adverse effects by investigating the patient background, plasma concentrations of proteins related with edoxaban metabolism, and genetic variants of cytochrome P450.
Basic objectives2
PK,PD
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Plasma concentrations of edoxaban and its metabolites just before dosing on the 4th day after starting medication or later.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Patients treated with edoxaban for atrial fibrillation
2. Patients receiving written informed consent
Key exclusion criteria
1. Patients discontinuing edoxaban
2. Patients who are judged by physicians as inappropriate for study enrollment
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | Junichi |
| Middle name | |
| Last name | Kawakami |
Organization
Hamamatsu University School of Medicine
Division name
Department of Hospital pharmacy
Zip code
4313192
Address
1-20-1 Handayama, Hamamatsu 431-3192
TEL
053-435-2763
pharmacyham-adm@umin.ac.jp
Public contact
Name of contact person
| 1st name | Kohei |
| Middle name | |
| Last name | Hoshikawa |
Organization
Hamamatsu University School of Medicine
Division name
Department of Hospital pharmacy
Zip code
4313192
Address
1-20-1 Handayama, Hamamatsu 431-3192
TEL
053-435-2763
Homepage URL
pharmacyham-adm@umin.ac.jp
Sponsor or person
Institute
Department of Hospital pharmacy
Hamamatsu University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Department of Hospital pharmacy
Hamamatsu University School of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Hamamatsu University School of Medicine
Address
1-20-1 Handayama, Hamamatsu 431-3192
Tel
053-435-2680
rinri@hama-med.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
浜松医科大学医学部付属病院（静岡県）
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 08 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2018 | Year | 09 | Month | 30 | Day |
Date of IRB
| 2018 | Year | 09 | Month | 05 | Day |
Anticipated trial start date
| 2018 | Year | 10 | Month | 07 | Day |
Last follow-up date
| 2023 | Year | 08 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Study design: Observational study
Object recruitment: All patients who visit our hospital and meet the selection criteria from September 2018 to August 2022
Primary outcome: Plasma concentrations of edoxaban and its metabolites like M1, M4, and M6 just before dosing on the 4th day after starting medication or later.
Secondary outcome:
1. Carboxylesterase activity in plasma and its genetic variants
2. Plasma levels of 4beta-hydroxycholesterol and 25-OH vitamin D
3. Polymorphisms of CYP3A4, CYP3A5, P450 oxidoreductase, ABCB1, and OATP1B1
4. Plasma inflammation biomarker and micro-RNA, such as miR-27a, miR-27b, miR-148a, miR-142, miR-30c-1-3p, miR-34a,miR-155, miR-223, miR-128a, miR-627, miR-206
5. Factors related to interindividual variation in plasma concentrations and metabolic ratios of edoxaban and its metabolites
6. Relationships between pharmacokinetics of edoxaban and its metabolites and plasma CYP3A biomarkers
7. Relationships between pharmacokinetics of edoxaban and its metabolites and plasma FXa activity biomarkers
8. Relationships between pharmacokinetics of edoxaban and its metabolites and their clinical effects
Management information
Registered date
| 2020 | Year | 07 | Month | 02 | Day |
Last modified on
| 2022 | Year | 07 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046802
